Project: Development of a rational, powerful, general and safe new therapy based on inhibition at several levels of the tumor neovasculature-specific integrin aVB3
- project duration
- 01-FEB-04 – 31-JAN-07
- The integrin aVB3 is an interesting drug target molecule in tumors. We will downregulate integrin-expression (by glucocorticoid receptor/HSP70), change its conformation (TNF/IFN), inhibit its substrate binding (RGDfV and tumstatin peptides) and block the association with MMPs (small drug and TIMPs). All approaches are based on our obtained results.